G. M. Rosa, L. Gigli, M. I. Tagliasacchi, D. Iorio, C. Carbone et al., Update on cardiotoxicity of anti-cancer treatments, Eur J Clin Invest, vol.46, pp.264-84, 2016.

M. Volkova and R. Russell, Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment, Curr Cardiol Rev, vol.7, pp.214-234, 2011.

M. Santoni, F. Guerra, A. Conti, A. Lucarelli, S. Rinaldi et al., Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies, Cancer Treat Rev, vol.59, pp.123-154, 2017.

R. J. Koene, A. E. Prizment, A. Blaes, and S. H. Konety, Shared risk factors in cardiovascular disease and cancer, Circulation, vol.133, pp.1104-1118, 2016.

B. Majed, T. Moreau, and B. Asselain, Curie Institute Breast Cancer Group. Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points, Breast Cancer Res Treat, vol.115, p.18546073, 2009.

B. Majed, T. Moreau, K. Senouci, R. J. Salmon, A. Fourquet et al., Is obesity an independent prognosis factor in woman breast cancer?, Breast Cancer Res Treat, vol.111, p.17939036, 2008.

E. E. Calle and R. Kaaks, Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms, Nat Rev Cancer, vol.4, pp.579-91, 2004.

A. G. Renehan, M. Tyson, M. Egger, R. F. Heller, and M. Zwahlen, Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet, vol.371, pp.569-78, 2008.

C. Guenancia, A. Lefebvre, D. Cardinale, A. F. Yu, S. Ladoire et al., Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis, J Clin Oncol, vol.34, pp.3157-65, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01413012

M. S. Mitra, S. Donthamsetty, B. White, and H. M. Mehendale, High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity, Toxicol Appl Pharmacol, vol.231, pp.413-435, 2008.

C. Guenancia, O. Hachet, M. Aboutabl, N. Li, E. Rigal et al., Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity, Cancer Chemother Pharmacol, vol.77, p.26914236, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01431557

I. Vaz-luis, P. Cottu, C. Mesleard, A. L. Martin, A. Dumas et al., UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer

. Esmo-open, , vol.4, p.562, 2019.

J. L. Zamorano, P. Lancellotti, R. Muñoz, D. Aboyans, V. Asteggiano et al., ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC), Eur Heart J, vol.37, pp.2768-801, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01788726

, Physical status: the use and interpretation of anthropometry, Report of a WHO Expert Committee. World Health Organ Tech Rep Ser, vol.14, pp.1-452, 1995.

S. Armenian, C. Lacchetti, A. Barac, J. Carver, L. Constine et al., Prevention and monitoring of cardiac dysfunction in survivors of adult cancers, J Clin Oncol, vol.35, pp.893-911, 2017.

J. V. Mcgowan, R. Chung, A. Maulik, I. Piotrowska, J. M. Walker et al., Anthracycline chemotherapy and cardiotoxicity, Cardiovasc Drugs Ther, vol.31, p.28185035, 2017.

A. Colombo, M. T. Sandri, M. Salvatici, C. M. Cipolla, and D. Cardinale, Cardiac complications of chemotherapy: role of biomarkers, Curr Treat Options Cardiovasc Med, vol.16, p.24771223, 2014.

S. Kongbundansuk and W. G. Hundley, Noninvasive imaging of cardiovascular injury related to the treatment of cancer, JACC Cardiovasc Imaging, vol.7, pp.824-862, 2014.

A. Nardi, I. Iakobishvili, and Z. , Cardiovascular risk in cancer survivors, Curr Treat Options Cardiovasc Med, vol.20, p.47, 2018.

M. Linschoten, A. J. Teske, M. J. Cramer, E. Van-der-wall, and F. W. Asselbergs, Chemotherapy-related cardiac dysfunction: a systematic review of genetic variants modulating individual risk, Circ Genom Precis Med, vol.11, 2018.

S. Kenchaiah, H. D. Sesso, and J. M. Gaziano, Body mass index and vigorous physical activity and the risk of heart failure among men, Circulation, vol.119, pp.44-52, 2009.

S. Kenchaiah and J. H. Chesebro, The epidemiologic association between obesity and heart failure, Am Coll Cardiol Ext Learn, vol.49, pp.4-6, 2017.

A. Hirayama, T. Goto, Y. J. Shimada, M. K. Faridi, C. A. Camargo et al., Association of obesity with severity of heart failure exacerbation: a population-based study, J Am Heart Assoc, vol.7, 2018.

M. Guglin, P. Munster, A. Fink, and J. Krischer, Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: a rationale and design of a randomized clinical trial, Am Heart J, vol.188, pp.87-92, 2017.

C. Koliaki, S. Liatis, and A. Kokkinos, Obesity and cardiovascular disease: revisiting an old relationship, Metabolism, vol.92, pp.98-107, 2019.

N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, Adipokines in inflammation and metabolic disease, Nat Rev Immunol, vol.11, pp.85-97, 2011.